<?xml version="1.0" encoding="UTF-8"?>
<p id="par0050">Novel anti-HSV-2 and anti-EV1 activities of emetine were discovered recently using CTG/plaque assays in human non-malignant RPE cells. Moreover, novel antiviral activities of the drug were identified using RFP-expressing RVFV, and GFP-expressing HMPV or FLUAV strains in RPE cells (
 <xref rid="bib0015" ref-type="bibr">Andersen et al., 2019a</xref>). Given that emetine also inhibits ZIKV, EBOV, RABV, CMV, HCoV-OC43 and HIV-1 infections (
 <xref rid="bib0070" ref-type="bibr">Chaves Valadao et al., 2015</xref>, 
 <xref rid="bib0285" ref-type="bibr">MacGibeny et al., 2018</xref>, 
 <xref rid="bib0320" ref-type="bibr">Mukhopadhyay et al., 2016</xref>, 
 <xref rid="bib0435" ref-type="bibr">Shen et al., 2019</xref>, 
 <xref rid="bib0540" ref-type="bibr">Yang et al., 2018</xref>), and that it is an FDA-approved anti-protozoal drug, it may represent a promising safe-in-man BSAA candidate.
</p>
